BioSpace News Archive

Drug Development

COVID-19 Vaccines: Employer Mandates, Boosters, New Studies and More

As the spread of the Delta variant exacerbates the COVID-19 pandemic, companies are increasingly moving toward requiring staffers to be vaccinated. Here’s a look at those stories and more.

August 5, 2021
·
4 min read
·
Mark Terry
Business

Kite Enters Allogenic Cell Therapy Collab with Startup Appia Bio for $875 Million

Gilead Sciences’ Kite Pharma has entered into a collaboration and licensing agreement with biotech startup Appia Bio, which will focus on the joint research and development of allogeneic cell therapies for cancer.

August 5, 2021
·
2 min read
·
Brandon May
Drug Development

Lung Cancer Drug Candidate Offers Patients Hope for Longer Life

The Phase III trial shows that PD-1 inhibitor Libtayo and platinum-doublet chemotherapy significantly improved OS compared with chemotherapy alone with locally advanced NSCLC.

August 5, 2021
·
2 min read
·
Brandon May
Drug Development

Study: Drug Candidate Improves Brain Energy Metabolism in Parkinson’s, MS

Top-line results from the Phase II REPAIR trial show a gold nanocrystal suspension, CNM-Au8®, significantly improved brain energetic metabolism in patients with Parkinson’s disease and multiple sclerosis.

August 5, 2021
·
3 min read
·
Brandon May
RNA Therapeutics Experience Renaissance Amidst Global Pandemic

RNA caught the public’s imagination in the form of mRNA vaccines against COVID-19, but RNA can be used in other ways, too, to make therapeutic proteins.

August 5, 2021
·
3 min read
·
Gail Dutton
Drug Development

First-Ever Single-Dose Chikungunya Vaccine Touts Positive Phase III Results

The announcement for the chikungunya vaccine (VLA1553) comes after the U.S. FDA awarded it with a Breakthrough Designation status. Read more about it here.

August 5, 2021
·
2 min read
·
Vanessa Doctor, RN
Genetown

Research Roundup: Getting the Inner Ear to Regenerate and More

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

August 5, 2021
·
5 min read
·
Mark Terry
Policy

CytoDyn Fights Back Against Activist Group

CytoDyn files a lawsuit against the activist group led by Rosenbaum and Patterson, alleging that they are “waging an illegal proxy contest to take over control of the Company’s Board of Directors.”

August 5, 2021
·
3 min read
·
Mark Terry
Job Trends

UK Watchdog Group Accuses Pfizer, Flynn Pharma of Price Gouging on Epilepsy Drug

A United Kingdom watchdog organization has accused Pfizer and Flynn Pharma of violating antitrust rules and overcharging that country’s National Health Services for anti-epilepsy treatments.

August 5, 2021
·
2 min read
·
Alex Keown
FDA

Eisai and Biogen Gun for Speedy Approval for Another Alzheimer’s Drug

Eisai said that they have initiated communication with the FDA to achieve “the most optimal regulatory pathway” for lecanemab.

August 5, 2021
·
2 min read
·
Vanessa Doctor, RN